SHANGHAI, July 16, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as 'Sanyou Bio') has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd.

上海，2024年7月16日/PRNewswire/--三友生物制药（上海）有限公司（以下简称“三友生物”）最近宣布与华东医药股份有限公司全资子公司杭州中美华东制药有限公司合作，取得了一个重要的里程碑。

(SZ.000963, hereinafter referred to as 'Huadong Medicine'). The jointly developed ADC drug, designated as project number SYHD001, has successfully entered Phase I clinical trials. This important milestone not only signifies substantial progress in the collaboration between the two parties but also serves as a powerful testimony to the cutting-edge technology platform of Sanyou Bio..

（SZ.000963，以下简称“华东医药”）。联合开发的ADC药物，指定为项目编号SYHD001，已成功进入I期临床试验。这一重要里程碑不仅标志着双方合作取得实质性进展，也有力地证明了三友生物的尖端技术平台。。

SYHD001, as an ADC drug, presents extremely high technical demands and development complexities. Sanyou Bio has laid a solid foundation for the successful development of the drug from the outset with its three innovative platforms for biologic drugs: Super-trillion molecule discovery platform, Integrated R&D platform, and Intelligent R&D platform.

SYHD001作为一种ADC药物，具有极高的技术要求和开发复杂性。三友生物从一开始就为该药物的成功开发奠定了坚实的基础，拥有三个创新的生物药物平台：超万亿分子发现平台、集成研发平台和智能研发平台。

Sanyou Bio completed the target research, raw material preparation, key molecule generation, assisted and cooperated in completing ADC conjugation and some in vitro and in vivo efficacy experiments, and helped the client to quickly and efficiently screen out compliant, high-expression, high-quality, and highly stable industrial cell lines for the project, thereby ensuring high-quality production and supply of ADC drugs and successfully promoting the project to rapidly complete IND filing and enter Phase I clinical trials..

三友生物完成了目标研究、原料制备、关键分子生成，协助和合作完成了ADC偶联以及一些体外和体内功效实验，并帮助客户快速有效地筛选出符合要求的、高表达的、高质量的、高度稳定的项目工业细胞系，从而确保了ADC药物的高质量生产和供应，并成功推动项目快速完成IND申报并进入I期临床试验。。

Dr. Guojun LANG, CEO of Sanyou Bio, said 'We are extremely honoured to collaborate with such an excellent partner as Huadong Medicine to advance SYHD001 to the clinical stage. In the future development, Sanyou Bio will continue to be committed to technological innovation and constantly enhance the core competitiveness of our own technology platform.

三友生物首席执行官郎国军博士表示，“我们非常荣幸与华东医药等优秀合作伙伴合作，将SYHD001推向临床阶段。在未来的发展中，三友生物将继续致力于技术创新，不断提升自身技术平台的核心竞争力。

We look forward to partnering with more collaborators to jointly promote the development of the biopharmaceutical industry and contribute more to the cause of human health.'.

我们期待与更多合作者合作，共同促进生物制药行业的发展，为人类健康事业做出更多贡献。”。

Since its establishment in 2015, Sanyou Bio has provided systematic solutions from target to IND to accelerate the drug development process through five key categories of innovative biologic drug R&D. The five key R&D stage services include: Target Discovery and Raw Material Preparation, Molecule Generation, Molecule Optimization, Pharmacology and Efficacy Analysis, and Cell line Development and Production Process..

自2015年成立以来，三友生物通过创新生物药物研发的五个关键类别，提供了从target到IND的系统解决方案，以加速药物开发过程。五个关键研发阶段服务包括：目标发现和原料制备，分子生成，分子优化，药理学和功效分析，以及细胞系开发和生产过程。。

To date, Sanyou Bio has served 1,000+ pharmaceutical clients, 7 CPO projects have been obtained IND approval, 10+ projects are in the preclinical R&D stage, 26 collaborative R&D projects are progressing in manner. It has extensive experiences covering 100+ PCC projects and 300+ antibody drug discovery projects, and has cooperated or assisted partners in publishing more than 50 papers, including top journals such as CNS..

迄今为止，三友生物已服务1000多家制药客户，7个CPO项目已获得IND批准，10多个项目处于临床前研发阶段，26个合作研发项目正在进行中。它拥有涵盖100多个PCC项目和300多个抗体药物发现项目的丰富经验，并合作或协助合作伙伴发表了50多篇论文，包括CNS等顶级期刊。。

About Huadong Medicine

关于华东医药

Huadong Medicine Co., Ltd. (SZ.000963) was founded in 1993, with its headquarters located in Hangzhou, Zhejiang. Adhering to the company value of 'Science Driven, Patient Centered', Huadong Medicine has gone through over 20 years of development, and has established a business presence covering the entire pharmaceutical industry chain, with four major business segments: pharmaceutical industry, pharmaceutical commerce, aesthetic medicine, and industrial microorganism, and has grown into a large comprehensive pharmaceutical listed company that integrates pharmaceutical R&D, manufacturing, and distribution.

华东医药股份有限公司成立于1993年，总部位于浙江杭州。华东医药秉承“科学驱动、以病人为中心”的公司价值观，经过20多年的发展，已建立起覆盖整个医药产业链的业务，拥有医药产业、医药商业、美容医学、工业微生物四大业务板块，已成长为集医药研发、制造、分销为一体的大型综合性医药上市公司。

In 2022, Huadong Medicine achieved a revenue of 37.715 billion yuan. With a current employee count exceeding ten thousand, the company possesses extensive commercial coverage and strong marketing capabilities..

2022年，华东医药实现收入377.15亿元。公司现有员工超过万人，拥有广泛的商业覆盖面和强大的营销能力。。

About Sanyou Bio

关于三友生物

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate 'differentiated CRO, integrated CDO, innovative CPO and characteristic CRS', to accomplish the mission 'to make the R&D easy for innovative biologics'..

三友生物制药有限公司是一家世界领先的高科技生物技术企业，专注于创新生物药物的研发和服务。三友已经建立了整合“差异化CRO、集成CDO、创新CPO和特色CRS”的4C商业模式，以完成“使创新生物制品的研发变得容易”的使命。。

Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by 'super-trillion, integration, and intelligence', which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc..

三友建立了设施先进的综合创新生物药物研发实验室，拥有一支以博士或硕士为主的专业团队。三友已经建立了“超万亿、集成、智能”三大行业领先的创新技术平台，由50多个子平台组成，以创新的超万亿噬菌体展示平台为核心，以材料制备、生物制剂发现、分子优化、体内外功效、生产细胞系建设、上下游工艺开发、临床前研发、产业化开发等平台为支撑。。

Sanyou's business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

三友的业务网络已扩展到世界各地，包括亚洲、美国和欧洲，并在波士顿、费城、圣地亚哥和伦敦设立了分支机构。三友与全球1000多家制药公司、药物研发机构和诊断公司建立了友好的业务关系。

Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification..

三友获得国家级高新技术企业和专业化、精细化企业认证，并通过ISO9001质量保证体系认证和GB/T知识产权管理体系认证。。

SOURCE Sanyou Bio

来源三友生物